← 治験一覧に戻る
局所進行性または転移性尿路上皮癌を有する日本人患者におけるエンホルツマブベドチンの臨床試験
基本情報
- NCT ID
- NCT03070990
- ステータス
- 完了
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 19
- 治験依頼者名
- Astellas Pharma Inc
概要
The objective of this study is to assess the safety, tolerability and pharmacokinetics of enfortumab vedotin (ASG-22CE) when administered intravenously to Japanese subjects with locally advanced or metastatic urothelial carcinoma. This study will also assess the immunogenicity as defined by the incidence of anti-drug antibody (ADA) and anti-tumor activity of enfortumab vedotin (ASG-22CE) when administered intravenously to Japanese subjects with locally advanced or metastatic urothelial carcinoma.
対象疾患
Metastatic Urothelial Cancer
介入
Enfortumab vedotin(DRUG)
依頼者（Sponsor）
Seagen(INDUSTRY)
アステラス製薬株式会社(INDUSTRY)